Candel Therapeutics reported extended phase 3 trial results showing aglatimagene besadenovec (CAN-2409) significantly improved prostate cancer-specific disease-free survival by 39% compared to placebo after a median follow-up of 58 months. The treatment also showed favorable trends in reducing metastasis and delaying additional cancer therapy, especially in intermediate-risk patients where a 90% reduction in time to metastasis was observed. These findings reinforce aglatimagene's potential to reduce tumor recurrence in localized prostate cancer patients undergoing radiotherapy. Candel plans to submit a Biologics License Application to the FDA in late 2026.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Thor Explorations produced 19,153 ounces of gold in Q2 2026 from its Segilola mine in Nigeria, maintaining its full-year production guidance of 75,000 to 85,000 ounces. The company generated $77.3 million in revenue by selling 17,050 ounces at an ave...
Angelini Pharma has finalized its $4.1 billion acquisition of Catalyst Pharmaceuticals, enhancing its footprint in the U.S. market and strengthening its global leadership in brain health and rare diseases. The deal includes significant investments fr...
Zcash (ZEC) has gained over 16% in the past week, rallying from lows near $368 to around $552 following an 11% jump in one session. This surge is driven by anticipation of the Ironwood shielded pool upgrade expected around July 28, which addresses a ...
Greenwich LifeSciences is developing GLSI-100, an immunotherapy targeting HER2-positive breast cancer, currently in Phase 3 trials. The drug showed a 70-80% reduction in cancer recurrence in Phase 2b, outperforming existing treatments with no serious...
